Blueprint Medicines to Buy Lengo Therapeutics for $250 Million Upfront

Blueprint Medicines has agreed to purchase Lengo Therapeutics, a biotech firm specializing in targeted cancer treatments, for an initial $250 million plus up to $215 million in milestones-based payments.

Under the deal, Blueprint will acquire Lengo’s lead candidate, LNG-451, a precision therapy being developed to treat nonsmall-cell lung cancer in patients with a specific type of genetic mutations, known as EGFR exon 20 insertion mutations.

Lengo plans to file an Investigational New Drug (IND) application with the FDA for LNG-451 this month.